Where wound science meets
patient access
Trulore Catalyst Group turns validated wound care technologies into active patient impact—skipping the bottlenecks that stall adoption. One point of access to ventures built on proven demand, not market speculation.
Reimagining how wound care ventures are built.
Most healthcare innovation follows a predictable, linear path:
Traditional development burns years and capital before anyone knows the market wants the product. Trulore Catalyst Group flips the sequence. We start with proven real-world demand, validate it inside live care environments, and build ventures around it, so partners and investors engage where the risk is already worked down.
Not years to market. Real-world validation at the point of care.
THE GAP
Wound care innovation is trapped in a broken pipeline.
The Legacy Model
The Consequence
The gap between discovery and the bedside, what the literature calls the "valley of death" in biomedical commercialization, is well documented ("Traversing the Valley of Death," 2023; National Academies of Sciences, Engineering, and Medicine, 2023). Yet the science of wound healing is clear on what matters: restoring the skin barrier and precisely regulating moisture are decisive determinants of healing outcomes (Peña & Martin, 2024; Wilkinson & Hardman, 2020).
Our Model
Trulore Catalyst Group inverted the pipeline.
Access first. Science always. Scale when it’s proven.
“From real-world insight to patient, without the bottleneck.”
Core Advantage
Access is the moat.
The platform is built on relationships most innovators spend years trying to reach, and many never do. Through the Trulore Catalyst Group ecosystem, every venture can draw on the same embedded access:
50,000+
Active patient touchpoints
700+
Provider feedback loops across care settings
50+
Skilled nursing operator partnerships
10,000+
Retail & Pharmacy Access Points
This is the difference between backing a venture on the platform and betting on a startup pitching from a lab. The hardest question, will anyone actually use this, is answered before the venture scales.
Platform
Identifying what should exist.
The Trulore commercialization engine identifies what should exist, builds it, validates it in real-world settings, and deploys it at scale.
Clinical Validation Engine
Embedded across thousands of facilities and active wound care touchpoints, our live patient cohorts generate continuous, real-world clinical data at scale.
Commercialization-First Architecture
Built by a consortium of physicians, wound care product developers, and facility operators who have outgrown a broken innovation pipeline that was keeping innovation from the bedside, we build for mass distribution from day one — before formulation begins.
Patient Access Layer
Integrated directly with hundreds of wound care clinicians and operators across skilled nursing and long-term care networks, we deliver immediate patient access at scale — equivalent to national deployment.
Innovation Gateway
A structured intake and deployment system that moves technologies from clinical need → validation → scaled distribution.
PORTFOLIO
Every venture begins with a real-world need.
Medical Device | Prescription Use
Dermaseal LITE Rx
FIRST-LINE TOPICAL ANTIMICROBIAL
Advanced wound management ointment formulated for clinical environments. Biocompatible wound matrix supporting autolytic debridement and optimal moisture balance.
Medical Device | Over-the-Counter
Dermaseal LITE OTC
ADVANCED WOUND MANAGEMENT DEVICE
Accessible wound healing ointment designed for everyday use. Includes precision applicator for controlled, hygienic application and moisture management.
Rx Drug | Chronic Wound Therapy
Dermaseal MAX
Chronic Wound Therapy
Dual-format treatment system combining ointment and powder for advanced wound care. Drug candidate advancing through clinical validation for diabetic foot ulcers and burn debridement.
For Innovators
Your science deserves patients, not just publications.
FOR INVESTORS & PARTNERS
Invest behind deployment, not speculation.
